Replimune Group - REPL Stock Forecast, Price & News

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on REPL shares. HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Replimune Group in a report on Tuesday, May 24th. SVB Leerink cut their price target on shares of Replimune Group from $48.00 to $37.00 and set an "outperform" rating on the stock in a report on Friday, August 5th. Wedbush cut their price target on shares of Replimune Group from $59.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday, May 24th. Finally, Piper Sandler cut their price target on shares of Replimune Group from $52.00 to $44.00 in a report on Thursday, May 19th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $46.00.

Replimune Group Stock Up 1.1 %

Shares of Replimune Group stock traded up $0.21 during trading on Friday, hitting $20.01. 419 shares of the company's stock were exchanged, compared to its average volume of 173,427. The company has a current ratio of 19.79, a quick ratio of 19.46 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $18.46 and a 200-day simple moving average of $17.33. Replimune Group has a 52-week low of $13.05 and a 52-week high of $35.93.

Replimune Group (NASDAQ:REPL - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.15). As a group, equities research analysts forecast that Replimune Group will post -2.85 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, CEO Philip Astley-Sparke sold 9,632 shares of Replimune Group stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $14.59, for a total value of $140,530.88. Following the sale, the chief executive officer now owns 1,401,080 shares in the company, valued at $20,441,757.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Pamela Esposito sold 3,507 shares of the firm's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $14.59, for a total value of $51,167.13. Following the transaction, the insider now directly owns 229,402 shares of the company's stock, valued at $3,346,975.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Philip Astley-Sparke sold 9,632 shares of the firm's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $14.59, for a total transaction of $140,530.88. Following the completion of the transaction, the chief executive officer now directly owns 1,401,080 shares in the company, valued at $20,441,757.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,899 shares of company stock worth $334,096. 23.80% of the stock is owned by company insiders.